Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 05:37:20 +0200Fri, 28 Jun 2024 12:00:00 +0200Summary of opinion: Imfinzi, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/imfinzi-0Summary of opinion: Imfinzi, 27/06/2024 Positivehttps://www.ema.europa.eu/en/medicines/human/variation/imfinzi-0Fri, 28 Jun 2024 12:00:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 20, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imfinziHuman medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 20, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/imfinziWed, 12 Jun 2024 10:18:00 +0200Human medicineImfinzi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4771-en_3.pdfImfinzi : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4771-en_3.pdfMon, 03 Jun 2024 15:45:00 +0200Human medicine